Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium Zirconium Cyclosilicate in Hyperkalemia (HARMONIZE Asia)
NCT03528681Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- May 2021
- Primary completion
- Sep 2022
- Modality
- DNA Intercalators/Alkylators
- Countries
- 2
01
Overview
A Phase 3 trial of sodium zirconium cyclosilicate in hyperkalemia, sponsored by AstraZeneca. Started May 2021; status: completed.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on NCT03528681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03528681.